In breast cancer, a pre-clinical study indicates that the MET inhibitor ARQ-197 can reduce bone metastasis induced by bone-seeking MDA-MB-231 metastatic breast cancer cells injected into mice [52]. This evidence concerns the gene MET and breast carcinoma.